TransCode Therapeutics, Inc., (RNAZ): Price and Financial Metrics
RNAZ Price/Volume Stats
| Current price | $3.35 | 52-week high | $83.16 |
| Prev. close | $3.35 | 52-week low | $2.66 |
| Day low | $3.23 | Volume | 31,700 |
| Day high | $3.45 | Avg. volume | 112,509 |
| 50-day MA | $7.90 | Dividend yield | N/A |
| 200-day MA | $18.82 | Market Cap | 2.33M |
RNAZ Stock Price Chart Interactive Chart >
TransCode Therapeutics, Inc., (RNAZ) Company Bio
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs for the treatment of metastatic diseases. The company's lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. Its products in discovery and preclinical stage include MicroRNA-10b, TTX-siPDL1, TTX-siLIN28b, and TTX-RIGA, which focuses on treating various cancers. The company was incorporated in 2016 and is based in Boston, Massachusetts.
RNAZ Price Returns
| 1-mo | -10.90% |
| 3-mo | -84.92% |
| 6-mo | -66.35% |
| 1-year | -87.91% |
| 3-year | -99.99% |
| 5-year | N/A |
| YTD | -0.59% |
| 2024 | -98.45% |
| 2023 | -98.78% |
| 2022 | -73.50% |
| 2021 | N/A |
| 2020 | N/A |
Loading social stream, please wait...